Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...
There was an error while loading. Please reload this page.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results